# Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy

> **NCT03502031** · PHASE4 · UNKNOWN · sponsor: **James A. Tumlin, MD** · enrollment: 72 (estimated)

## Conditions studied

- Renal Insufficiency, Chronic
- Diabetic Nephropathy Type 2

## Interventions

- **DRUG:** Renin-Angiotensin (RAAS) alone
- **DRUG:** Renin-Angiotensin (RAAS) blockers in combination with Spironolactone

## Key facts

- **NCT ID:** NCT03502031
- **Lead sponsor:** James A. Tumlin, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2022-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2022-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03502031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03502031, "Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03502031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*